Curis Says FDS Allows Additional Patient Enrollment For TakeAim Leukemia Study
WASHINGTON (dpa-AFX) - Curis, Inc. (CRIS), a biotechnology firm focused on cancer treatment, said on Tuesday that the U.S. Food and Drug Administration or FDA has notified that it may resume addit…
Curis Says FDS Allows Additional Patient Enrollment For TakeAim Leukemia Study
WASHINGTON (dpa-AFX) - Curis, Inc. (CRIS), a biotechnology firm focused on cancer treatment, said on Tuesday that the U.S. Food and Drug Administration or FDA has notified that it may resume addit…